NCT01489813View on ClinicalTrials.gov

Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 19, 2017

Primary Completion Date

August 31, 2023

Study Completion Date

August 31, 2024

Conditions
Bladder Cancer
Interventions
DRUG

Genistein

30 mg of genistein supplement by mouth three times daily (PO TID).

DRUG

Sugar pill

Sugar pills will be taken by mouth three times daily (PO TID).

Trial Locations (3)

30308

Emory University Hospital Midtown, Atlanta

30322

Emory University Department of Urology, Atlanta

30342

Emory Saint Joseph's Hospital, Atlanta

All Listed Sponsors
collaborator

DSM Nutritional Products, Inc.

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institutes of Health (NIH)

NIH

lead

Emory University

OTHER

NCT01489813 - Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment | Biotech Hunter | Biotech Hunter